I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ESMO 2019 Congress

The annual ESMO Congress brings together oncology professionals from around the world to discuss the latest advances in the field.

 

Boehringer Ingelheim is dedicated to collaborating with the oncology community on a shared journey to deliver leading science. At the ESMO 2019 Congress we will be holding a symposium on treatment decisions for advanced non-small cell lung cancer (NSCLC), as well as presenting data highlighting recent findings in the treatment of lung cancer. Please see below for further details.

 

For more information on the ESMO 2019 Congress, click here.

1 symposium
Booth #401
View Expo Plan
Fira Gran Via, Barcelona, Spain
27 September–1 October 2019
Making first- and second-line treatment decisions for advanced NSCLC
symposium_cal
29 September 2019
symposium_cal
13:00pm - 14:30pm
symposium_cal
Hall 3, Salamanca Auditorium

Join us at our ESMO symposium to hear an international faculty of experts discuss first-line treatment decisions for EGFR mutation-positive NSCLC and second-line treatment decisions for advanced NSCLC, including squamous cell carcinoma and non-oncogene addicted, non-squamous disease.

        James Yang, National Taiwan University

James Yang, National Taiwan University

Chair; Moderator of Q&A sessions

Common options for uncommon mutations

        Barbara Melosky, University of British Columbia

Barbara Melosky, University of British Columbia

Sequencing to prolong the chemotherapy-free period

        Noemi Reguart, Hospital Clinic Barcelona

Noemi Reguart, Hospital Clinic Barcelona

Squamous NSCLC: where do EGFR TKIs fit in?

        Maximillian Hochmair, Otto Wagner Hospital

Maximillian Hochmair, Otto Wagner Hospital

Non-mutated, non-squamous NSCLC (adenocarcinoma): failing first-line immunotherapy + chemotherapy, what now?

Publications

Come and find out more about our emerging data during the scientific programme at the ESMO 2019 Congress. Please revisit this page for further details about our presentations nearer the time of the congress.

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: July 2019